CLAIMS:

1. A method of diagnosing a subject as having a coronavirus-induced disease, wherein the disease is characterized by mast cell degranulation, acute inflammation, pulmonary pathology and/or vascular pathology, the method comprising:

(a) obtaining a biological sample from the subject;

(b) determining the level and/or activity of at least one biomarker in the biological sample from the subject, wherein the biomarker is a mast cell protease, preferably selected from the group consisting of chymase and tryptase;

(c) comparing the level and/or activity of the at least one biomarker in the biological sample to a reference level and/or activity of the at least one biomarker;

(d) identifying the subject as having the disease or having an increased risk of developing the disease if the level and/or activity of the at least one biomarker is greater than the reference level and/or activity of the at least one biomarker.

2. The method of claim 1, wherein the reference level and/or activity is from a sample from a healthy patient, a patient having a mild form of the coronavirus-induced disease, or a patient having a severe form of the coronavirus-induced disease.

3. The method of claim 1 or 2, wherein:

a) a mast cell protease level and/or activity greater than 1 standard deviation above the mean for patients during acute disease or during disease resolution indicates the subject should be monitored for severe disease and/or complications; or

b) a mast cell protease level above a normal level of about 300 pg/mL for tryptase or 3 ng/mL for chymase indicates the subject should be monitored for severe disease.

4. The method of any one of claims 1 to 3, wherein the coronavirus is selected from the group consisting of Severe Acute Respiratory Syndrome-associated coronavirus (SARS-CoV), SARS-CoV-2 and Middle East Respiratory Syndrome-associated coronavirus (MERS-CoV).

5. A method of monitoring the efficacy of a method of prophylaxis or treatment of a coronavirus-induced disease, wherein the disease is characterized by mast cell degranulation, acute inflammation, pulmonary pathology, vascular pathology wherein a subject has been administered a composition comprising a mast cell stabilizer and/or inhibitor of mast cell products, wherein;

the mast cell stabilizer is selected from one or more of a group consisting of cromolyn, nedocromil, pemirolast, lodoxamide, tranilast, glucosamine, N-acetylglucosamine, FPL 52694, aloe vera, quercetin, chondroitin sulfate, dehydroleucodine, mast cell stabilizer TF002, rupatadine, loratadine, cetirizine, clemastime, fexofenadine, diphenhydramine, chlorpheniramine, azelastine, olopatadine, naphazoline, ketotifen, emedastine, ebrotidine, calcium channel blocker, a cytochrome P450 inhibitor, a histamine antagonist,
and the inhibitor of mast cell products is selected from one or more of a group consisting of zafirlukast, ketanserin, montelukast, pranlukast, zileuton, SM-12502, rupatadine, PAF-targeting antibodies, xanthine derivatives, methylxanthines like theophylline oxtriphylline, dyphylline, aminophylline, bupropion, curcumin, catechins, aprotinin, serpin, a chymase inhibitor, TY-51469, chymostatin, leupeptin, APC-336, SUN-C8257, NK3201, RO566852, BCEAB, NK3201, TEI-E548, APC-2095, RWJ-355871, TPC-806, ZIGPFM, AAPF-S-Bzl, Bowman-Birk soybean protease inhibitor, BI-1942, TEI-f00806, BAY-1142524, fulacimstat, ASB17061, Polygonum, SFTI-1 and derivatives, bevacizumab, ranibizumab, lapatinib, sunitinib sorafenib, axitinib, pazopanib, thiazolidinediones, benzoxazole, benzthiazole, benzinidzole, CP105,696, laropiprant, acetylsalicylic acid (ASA), indomethacin, sodium meclofenamate (FEN), phenylbutazone (PB), phloretin phosphates (PP), SC-19220, diethylcarbamazine citrate (DECC), protamine and polybrene, a tryptase inhibitor, nafamostat mesylate, BMS-262084, BMS-363131, BSM-36130, Guanadino β-lactams that inhibit tryptase, delta inhibitors of tryptase, benzamidine dimers that inhibit tryptase, piperidine containing 4-carboxy azetidinone tryptase inhibitors, APC-2059, BAY 443428, phenylglycylcarbonyl benzylamines, Peptidyl heterocyclic ketones, Guanidino Bicyclic lactam, Amino or Amidino dimers, Peptidomimetic inhibitors, MOL-6131, RWJ-56423, RWJ-58643, RWJ-51084, BABIM (bis-(5-amidino-2-benzimidazoyl) methane, APD-8, AMG-126737, 4-chlorobenzyoyl ester of 4-hydroxytetronic acid and its *p*-toluate tetronic acid derivatives, M-58538, AY-0068, PMD-3027, Cyclotheonamide E4 and E5, and amidinobenzofuran derivatives,
comprising serially measuring the level and/or activity of a mast cell protease, preferably selected from the group consisting of chymase and tryptase, in at least one sample from said subject.

6. The method of claim 5, wherein said mast cell stabilizer and/or inhibitor of mast cell products are selected from the group consisting of ketotifen [IUPAC Name: 2-(1-methylpiperidin-4-ylidene)-6-thiatricyclo[8.4.0.03,7] tetradeca-1(14),3(7),4,10,12-pentaen-8-one ], cromolyn [IUPAC Name: 5-[3-(2-carboxy -4-oxochromen-5-yl)oxy-2-hydroxypropoxy]-4-oxochromene-2-carboxylic acid], nafamostat mesylate [IUPAC Name: (6-

carbamimidoylnaphthalen-2-yl) 4-(diaminomethylideneamino)benzoate;methanesulfonic acid], TY-51469 [IUPAC Name 2-[4-[(5-fluoro-3-methyl-1-benzothiophen-2-yl)sulfonylamino]-3-methylsulfonylphenyl]-1,3-thiazole-4-carboxylic acid] and ketanserin [IUPAC Name: 3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-1H-quinazoline-2,4-dione].

7. The method of claim 6, wherein;
-cromolyn is formulated for administration to adults at 200 mg or more 4x a day, and children at 100 mg or more 4x a day;
-ketotifen is formulated for administration orally at 1 mg or more per day in adults or 0.110 mg or more per pound of body weight including for children;
-nafamostat mesylate is formulated for administration at 20-50 mg or more infusion, or 2-10 mg/kg or more per day;
-TY-51469 is formulated for administration at 0.1-100 mg/kg or more per day; and/or
-Ketanserin is formulated for administration at 10-100 mg or more twice a day.

8. Use of a composition for the manufacture of a medicament for the prophylaxis or treatment of a coronavirus-induced disease, wherein the disease is characterized by mast cell degranulation, acute inflammation, pulmonary pathology and/or vascular pathology,
wherein the composition comprises a mast cell stabilizer and/or inhibitor of mast cell products, wherein;
the mast cell stabilizer is selected from one or more of a group consisting of cromolyn, nedocromil, pemirolast, lodoxamide, tranilast, glucosamine, N-acetylglucosamine, FPL 52694, aloe vera, quercetin, chondroitin sulfate, dehydroleucodine, mast cell stabilizer TF002, rupatadine, loratadine, cetirizine, clemastime, fexofenadine, diphenhydramine, chlorpheniramine, azelastine, olopatadine, naphazoline, ketotifen, emedastine, ebrotidine, calcium channel blocker, a cytochrome P450 inhibitor, a histamine antagonist,
and the inhibitor of mast cell products is selected from one or more of a group consisting of zafirlukast, ketanserin, montelukast, pranlukast, zileuton, SM-12502, rupatadine, PAF-targeting antibodies, xanthine derivatives, methylxanthines like theophylline oxtriphylline, dyphylline, aminophylline, bupropion, curcumin, catechins, aprotinin, serpin, a chymase inhibitor, TY-51469, chymostatin, leupeptin, APC-336, SUN-C8257, NK3201, RO566852, BCEAB, NK3201, TEI-E548, APC-2095, RWJ-355871, TPC-806, ZIGPFM, AAPF-S-Bzl, Bowman-Birk soybean protease inhibitor, BI-1942, TEI-f00806, BAY-1142524, fulacimstat, ASB17061, Polygonum, SFTI-1 and derivatives, bevacizumab, ranibizumab, lapatinib, sunitinib sorafenib, axitinib, pazopanib, thiazolidinediones, benzoxazole, benzthiazole, benzinidzole, CP105,696, laropiprant, acetylsalicylic acid (ASA), indomethacin, sodium

meclofenamate (FEN), phenylbutazone (PB), phloretin phosphates (PP), SC-19220, diethylcarbamazine citrate (DECC), protamine and polybrene, a tryptase inhibitor, nafamostat mesylate, BMS-262084, BMS-363131, BSM-36130, Guanadino β-lactams that inhibit tryptase, delta inhibitors of tryptase, benzamidine dimers that inhibit tryptase, piperidine containing 4-carboxy azetidinone tryptase inhibitors, APC-2059, BAY 443428, phenylglycylcarbonyl benzylamines, Peptidyl heterocyclic ketones, Guanidino Bicyclic lactam, Amino or Amidino dimers, Peptidomimetic inhibitors, MOL-6131, RWJ-56423, RWJ-58643, RWJ-51084, BABIM (bis-(5-amidino-2-benzimidazoyl) methane, APD-8, AMG-126737, 4-chlorobenzyoyl ester of 4-hydroxytetronic acid and its *p*-toluate tetronic acid derivatives, M-58538, AY-0068, PMD-3027, Cyclotheonamide E4 and E5, and amidinobenzofuran derivatives.

9. The use of claim 8, wherein the coronavirus is selected from the group consisting of SARS-CoV, SARS-Cov-2 and MERS-CoV.

10. The use of claim 8 or 9, wherein said mast cell stabilizer and/or inhibitor of mast cell products are selected from the group consisting of ketotifen [IUPAC Name: 2-(1-methylpiperidin-4-ylidene)-6-thiatricyclo[8.4.0.03,7] tetradeca-1(14),3(7),4,10,12-pentaen-8-one ], cromolyn [IUPAC Name: 5-[3-(2-carboxy -4-oxochromen-5-yl)oxy-2-hydroxypropoxy]-4-oxochromene-2-carboxylic acid], nafamostat mesylate [IUPAC Name: (6-carbamimidoylnaphthalen-2-yl) 4-(diaminomethylideneamino)benzoate;methanesulfonic acid], TY-51469 [IUPAC Name 2-[4-[(5-fluoro-3-methyl-1-benzothiophen-2-yl)sulfonylamino]-3-methylsulfonylphenyl]-1,3-thiazole-4-carboxylic acid] and ketanserin [IUPAC Name: 3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-1H-quinazoline-2,4-dione].

11. The use of claim 10, wherein the composition comprises:
i) cromolyn formulated for administration at 200 mg or more 4x a day (adults), or at 100 mg or more 4x a day (children);
ii) ketotifen formulated for administration at 1 mg or more per day (adults) or at 0.110 mg or more per pound of body weight (adults or children);
iii) nafamostat, formulated for administration at 20-50 mg or more by infusion, or 2-10 mg/kg or more per day;
iv) TY-51469, formulated for administration at 0.1-100 mg/kg or more per day; and/or
v) Ketanserin, and is formulated for administration at 10-100 mg or more twice a day.

12. The use of claim 8 or 9, wherein the composition comprises:

a) ketotifen and indomethacin;

b) ketotifen and loratadine;

c) ketotifen and fexofenadine;

d) ketotifen and cetirizine;

e) cromolyn and indomethacin;

f) cromolyn and loratadine;

g) cromolyn and fexofenadine; or

h) cromolyn and cetirizine.